{"id":913,"date":"2017-07-26T23:07:59","date_gmt":"2017-07-27T04:07:59","guid":{"rendered":"http:\/\/www.creative-biolabs.com\/blog\/?p=913"},"modified":"2018-04-18T01:03:41","modified_gmt":"2018-04-18T06:03:41","slug":"situation-of-egfr-drugs","status":"publish","type":"post","link":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/situation-of-egfr-drugs\/","title":{"rendered":"A Quick View of the Global R&#038;D Situation of EGFR Drugs"},"content":{"rendered":"<p>1. There are 102 EGFR-targeted drugs that are approved globally and in clinical research in total.<\/p>\n<p>Up to now, there are 20 EGFR-targeted drugs approved by the global market (Europe, USA, Japan, South Korea, etc.), 80 in clinical application and research stage, and 2 in NDA application.<\/p>\n<p><a href=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug1.png\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-full wp-image-914\" src=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug1.png\" alt=\"EGFR-targeted drugs\" width=\"590\" height=\"327\" srcset=\"https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug1.png 590w, https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug1-300x166.png 300w\" sizes=\"(max-width: 590px) 100vw, 590px\" \/><\/a><\/p>\n<p>2. EGFR-targeted drugs are mainly small molecule inhibitors.<\/p>\n<p>Molecular targeting drugs developed for EGFR are divided into two major categories:<\/p>\n<p>1)\u00a0There are 18 monoclonal antibodies, such as <strong><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/www.creativebiolabs.net\/Cetuximab-32082.htm\" target=\"_blank\">cetuximab<\/a><\/span><\/strong> and <strong><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/www.creativebiolabs.net\/Panitumumab-22418.htm\" target=\"_blank\">panitumumab<\/a><\/span><\/strong>. They can bind to EGFR extracellular region and block ligand-dependent EGFR activation.<\/p>\n<p>2)\u00a0There are 68 small molecule inhibitors, including small molecule multi-target receptor tyrosine kinase (RTKs) Inhibitors and small molecule tyrosine kinase inhibitors (EGFR-TKls), which can inhibit tyrosine kinase\u2019s activity in EGFR intracellular region.<\/p>\n<p><a href=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug21.png\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-full wp-image-916\" src=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug21.png\" alt=\"Small molecule inhibitors\" width=\"380\" height=\"219\" srcset=\"https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug21.png 380w, https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug21-300x173.png 300w\" sizes=\"(max-width: 380px) 100vw, 380px\" \/><\/a><\/p>\n<p>3.\u00a09 EGFR small molecule inhibitor drugs are approved.<\/p>\n<p>1) AstraZeneca has 3 approved drugs, occupying one third of the global market.<\/p>\n<p>2) The approved EGFR small molecule inhibitors are mainly sued for the treatment of non-small cell lung cancer.<\/p>\n<p><a href=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug3.png\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-full wp-image-917\" src=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug3.png\" alt=\"9 EGFR small molecule inhibitor drugs are approved\" width=\"746\" height=\"483\" srcset=\"https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug3.png 746w, https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug3-300x194.png 300w\" sizes=\"(max-width: 746px) 100vw, 746px\" \/><\/a><\/p>\n<p>3) In the United States, there are 8 approved EGFR small molecule inhibitor drugs which have patent protection. Gefitinib is confronting with patent cliff.<\/p>\n<p><a href=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug4.png\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-full wp-image-918\" src=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug4.png\" alt=\"8 approved EGFR small molecule inhibitor drugs\" width=\"573\" height=\"334\" srcset=\"https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug4.png 573w, https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug4-300x175.png 300w\" sizes=\"(max-width: 573px) 100vw, 573px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p>4.\u00a04 EGFR-targeted monoclonal antibodies are approved.<\/p>\n<p>1)\u00a0Antibody class EGFR-targeted drugs are mainly used for the treatment of rectal cancer, head and neck cancer.<\/p>\n<p>2)\u00a0Eli Lilly has 2 approved drugs, dominating the EGFR monoclonal antibody market.<\/p>\n<p>3)\u00a0Cetuximab is the champion of the year, with sales twice as much as panitumumab of the same indication.<\/p>\n<p><a href=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug-6.png\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-full wp-image-919\" src=\"http:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug-6.png\" alt=\"4 EGFR-targeted monoclonal antibodies are approved.\" width=\"693\" height=\"481\" srcset=\"https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug-6.png 693w, https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2017\/07\/egfr-drug-6-300x208.png 300w\" sizes=\"(max-width: 693px) 100vw, 693px\" \/><\/a><\/p>\n<p><strong>Notes:<\/strong> The global sales showed in the histogram are the original sales of the relevant company. The above data was retrieved on July 12, 2017.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>1. There are 102 EGFR-targeted drugs that are approved globally and in clinical research in total. Up to now, there are 20 EGFR-targeted drugs approved by the global market (Europe, USA, Japan,<a class=\"moretag\" href=\"https:\/\/www.creative-biolabs.com\/blog\/index.php\/situation-of-egfr-drugs\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[108],"tags":[61,63,64,65,62],"_links":{"self":[{"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/posts\/913"}],"collection":[{"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/comments?post=913"}],"version-history":[{"count":2,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/posts\/913\/revisions"}],"predecessor-version":[{"id":921,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/posts\/913\/revisions\/921"}],"wp:attachment":[{"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/media?parent=913"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/categories?post=913"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/tags?post=913"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}